1950 |
Synthesis of chlorpromazine[3] |
1952 |
Preliminary evidence of antipsychotic effect of chlorpromazine[6,7,11] |
1958 |
Synthesis of haloperidol[16] |
1960 |
Parkinson basal ganglia are deficient in dopamine[19] |
1963 |
Neuroleptics raise level of monoamine metabolites[18] |
1966 |
Neuroleptics may antagonize dopamine receptors[26] |
1971 |
2 nmol haloperidol in plasma effective in psychosis[34] |
1974 |
Synthesis of (+-) butaclamol[36] |
1975 |
Tritiated haloperidol binds DA receptors[38] |
1975 |
Effective neuroleptic dose correlates with D2 block[39] |
1979 |
Multiple dopamine receptors[54] |
1984 |
Bimodal D2 distribution in schizophrenia[45] |
1984 |
High and low affinity states for D2[58] |
1988 |
Cloning of the D2 receptor[63] |
1988 |
In vivo imaging of D2 occupancy[47] |
1990 |
Cloning of D3[67] |
1999 |
Fast-off theory[71] |
2000 |
Multiple genetic variants of D2 receptor[73-75] |
2000 |
Impact of the D3 receptor[81] |
2005 |
Impact of other neurotransmitter receptors[83] |
2010 |
Impact of receptor heterodimers[85] |
2017 |
Impact of D2 high affinity state[77] |
2021 |
Structure and specificities of D1, D2 signaling complexes[79] |